Il28b alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Abu Dayyeh, Barham K ^a,b   Gupta, Namrata ^c   Sherman, Kenneth E ^d   de Bakker, Paul I W ^c,e,f   Chung, Raymond T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IL28B GENE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); PHARMACOGENETICS; PREDICTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ALLELES; COHORT STUDIES; COINFECTION; DRUG SYNERGISM; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROBABILITY; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 80053928948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025753     Document Type: Article

References (41)

1. Sulkowski MS, Mast EE, Seeff LB, Thomas DL, (2000) Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 30 (Suppl 1): S77-84.
2. Verucchi G, Calza L, Manfredi R, Chiodo F, (2004) Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 32: 33-46.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497.
4. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, et al. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33: 240-247.
5. Chen TY, Ding EL, Seage GR Iii, Kim AY, (2009) Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 49: 1605-1615.
6. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166: 1632-1641.
7. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB, (2004) Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 164: 2349-2354.
8. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, et al. (2007) Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46: 622-630.
9. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, et al. (2004) Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351: 451-459.
10. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, et al. (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351: 438-450.
11. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, et al. (2007) Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21: 1073-1089.
12. Kau A, Vermehren J, Sarrazin C, (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49: 634-651.
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, et al. (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652.
14. Laguno M, Larrousse M, Murillas J, Blanco JL, Leon A, et al. (2007) Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr 44: 174-178.
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
16. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
17. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
18. Balagopal A, Thomas DL, Thio CL, (2010) IL28B and the control of hepatitis C virus infection. Gastroenterology 139: 1865-1876.
19. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, et al. (2011) IL28B inhibits Hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55: 289-298.
20. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345, 1345 e1331-1337.
21. Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, et al. (2011) Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-naive Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol 9: 344-350.
22. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2011) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439-448.
23. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, et al. (2011) HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60: 261-267.
24. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, et al. (2010) Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24: F23-29.
25. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51: 788-795.
26. Aparicio E, Parera M, Franco S, Perez-Alvarez N, Tural C, et al. (2010) IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 5: e13771.
27. Clausen LN, Weis N, Astvad K, Schonning K, Fenger M, et al. (2011) Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 18: e66-74.
28. Medrano J, Neukam K, Rallon N, Rivero A, Resino S, et al. (2010) Modeling the probability of sustained virological response to Therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 51: 1209-1216.
29. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-129 e118.
30. Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, et al. (2010) Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). J Acquir Immune Defic Syndr. [Published online before print].
31. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response than IL28B Genotype in Patients with Hepatitis C. Gastroenterology 140: 1021-1031.
32. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509.
33. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.
34. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, et al. (2011) IL28 Variation Affects Expression of Interferon Stimulated Genes and Effect of Peg-Interferon and Ribavirin Therapy. J Hepatol 54: 1094-1101.
35. Thio CL, Thomas DL, (2010) Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology 138: 1240-1243.
36. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96: 224-230.
37. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, et al. (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380.
38. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, et al. (2009) Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 44: 952-963.
39. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46: 403-410.
40. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
41. Morgan TR, O'Brien TR, (2011) IL28B-Genotype Testing Now and in the Era of Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol 9: 293-294.